Ranolazine Tablet, Extended Release
Product Images NDC 42571-324

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 42571-324). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ranolazine Lbl A

This is a medication label for Extended-Release Ranolazine tablets, manufactured by Micro Labs Limited in India. The package insert provides information on dosage and administration, and the tablets should be swallowed whole and stored at room temperature. The label includes a National Drug Code number for prescription use, and warns not to crush, break, or chew the tablets. The label also provides the manufacturer's information and a revision date of October 2021.*

FDA Label Image

Ranolazine Lbl B

This is a pharmaceutical product packaging for Ranolazine, an extended-release tablet used to treat chronic angina. The package contains 60 tablets, each tablet being 1,000mg. The tablets should be swallowed whole and not crushed or broken. The dosage for the medication is available in the package insert, and the product should be stored at 25°C (77°F), and should not be exposed to temperatures lower than 15°C or higher than 30°C. The manufacturer of Ranolazine is Micro Labs Limited in Goa, India.*

FDA Label Image

Structure (Ranolazine Strct)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.